✦ LIBER ✦

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

✍ Scribed by Nathalie Theou-Anton, Sandrine Faivre, Chantal Dreyer, Professor Eric Raymond

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Benefit-Risk Assessment of Imatinib in

✍ Dominik Wolf, Holger Rumpold 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 286 KB

Risk assessment and pathological reporti

✍ Agaimy, Abbas 📂 Article 📅 2013 🏛 Elsevier 🌐 English ⚖ 719 KB

Nilotinib in the treatment of advanced g

✍ M. Montemurro; P. Schöffski; P. Reichardt; H. Gelderblom; J. Schütte; J.T. Hartm 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 156 KB

1140 POSTER Asthenia and Fatigue as Pred

✍ M.P. Davis; D. Goldstein; S. George; R.G. Casali; S. Li; J. Perkins; G.D. Demetr 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Comparison of performance of various tum

✍ Shinagare, Atul B.; Jagannathan, Jyothi P.; Kurra, Vikram; Urban, Trinity; Manol 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 409 KB

Sunitinib malate in the treatment of ren

✍ Jayesh DESAI; Howard GURNEY; Nick PAVLAKIS; Grant A McARTHUR; Ian D DAVIS 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB